AbbVie

Photo
04.03.2025 • News

AbbVie Teams up with Gubra to Develop Obesity Treatment

The US pharmaceutical giant AbbVie and Danish biotechnology company Gubra, specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, signed a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.

Photo
18.12.2024 • News

AbbVie to Buy Nimble Therapeutics for $200 Million

US biopharma AbbVie has signed an agreement to acquire US biotechnology company Nimble Therapeutics, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases.

Photo
30.10.2024 • News

AbbVie to Buy US Biotech Firm Aliada for $1.4 Billion

US drugmaker AbbVie has signed an agreement to acquire biotechnology company Aliada Therapeutics, which develops therapies for central nervous system (CNS) diseases using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases.

Photo
06.08.2024 • News

AbbVie Completes Acquisition of Cerevel Therapeutics

AbbVie has completed its acquisition of Cerevel Therapeutics. According to AbbVie, Cerevel's pipeline is highly complementary to its own existing neuroscience portfolio. The takeover was announced in December 2023.

Photo
29.06.2024 • News

AbbVie Acquires Celsius Therapeutics

AbbVie has acquired Celsius Therapeutics, a privately held biotechnology company developing new therapies inflammatory diseases, for $250 million in cash. The transaction is subject to certain customary adjustments.

Photo
30.01.2024 • News

AbbVie to Build New Biologics Manufacturing Site in Singapore

Last week, AbbVie broke ground on a new Singapore manufacturing facility located in Singapore's Tuas Biomedical Park. The company will invest $223 million in the site which will add 24,000 l of biologics drug-substance capacity to AbbVie's global manufacturing network and support current products as well as emerging immunology and oncology compounds within its pipeline.

Photo
07.12.2023 • News

AbbVie to Acquire Cerevel Therapeutics for $8.7 Billion

In a move to complement its neuroscience portfolio, US drugmaker AbbVie has agreed to acquire Cerevel Therapeutics, which has a pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders.

Photo
01.12.2023 • News

AbbVie to Buy Cancer Drug Maker ImmunoGen for $10.1 Billion

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

Photo
13.09.2023 • TopicsPharma

The Success Story of Biosimilars

With their triumphant advance, biosimilars are also setting in motion the usual market mechanisms. Biopharma interest groups warn against the automatic substitution of originator drugs.

Photo
09.03.2022 • News

AbbVie Expands Neuroscience Portfolio with Syndesi Purchase

US biopharma AbbVie is to take over Belgian biotech Syndesi Therapeutics, in a move that will expand its neuroscience portfolio. Under the agreed terms, AbbVie will pay Syndesi shareholders an upfront sum of $130 million, with potential additional payments of up to $870 million contingent on achieving certain milestones.

Photo
17.09.2021 • News

AbbVie and Regenxbio Link on Eye Diseases

US biopharmas AbbVie and Regenxbio are forming a strategic partnership to develop and commercialize a gene therapy for eye diseases. The transaction is expected to close by the end of 2021, subject to customary closing conditions and regulatory approvals.

Photo
22.03.2021 • News

AbbVie to Sell off Allergan Women’s Health Portfolio

US pharma AbbVie has put compatriot Allergan’s women’s health business up for sale. The company is said to be working with Morgan Stanley on an auction process that has attracted interest from private equity firms including CVC Capital Partners. Reuters, which broke the story, said AbbVie’s existing women’s health franchise before picking up Allergan is not part of the sale.

Photo
18.02.2021 • News

AbbVie and Caribou in CAR-T Collaboration

US biopharma AbbVie and compatriot biotech Caribou Biosciences have entered into a multi-year collaboration and license agreement to research and develop chimeric antigen receptor (CAR)-T cell therapeutics.

Photo
11.09.2020 • News

AbbVie and I-Mab in Cancer Collaboration

US biopharma AbbVie has signed a global collaboration agreement with China’s I-Mab to develop and commercialize lemzoparlimab – also known as TJC4 – an anti-CD47 monoclonal antibody for treating multiple cancers. The companies can also potentially expand the collaboration to include other therapies.

42 more articles

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis